Taysha Gene Therapies, Inc. (TSHA) Operating income 2020–2025
Taysha Gene Therapies, Inc. (TSHA) annual operating income history from SEC filings — each fiscal year as reported.
-$110.5MFY2025 · since FY2020: -$43.0M → -$110.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$110.5M | -20.8% |
| FY2024 | -$91.5M | -26.3% |
| FY2023 | -$72.4M | +55.4% |
| FY2022 | -$162.4M | +6.2% |
| FY2021 | -$173.3M | -302.9% |
| FY2020 | -$43.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Net marginTSHA Gross profitTSHA Gross marginTSHA Operating marginTSHA Operating cash flowTSHA Free cash flowTSHA Capital expendituresTSHA Return on equityTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Total liabilitiesTSHA Shareholders’ equityTSHA overview →